The objective of the FLURESP consortium is to redefine main human pandemic scenarios at the European level, describe and cluster possible response strategies and assess these response strategies in the frame of multi-criteria and cost-effectiveness analyses, taking into account lessons from the 2009 pandemic situation in Europe. Human pandemic scenarios and main related responses have never been assessed and ranked using both multi-criteria and cost-effectiveness approaches. It appears urgent to develop a strategy relying on assessment of lessons learnt with respect to improving intersectorial collaboration and cross-border coordination in responding to health emergencies. The integrated approach of Decision Making proposed by the FLURESP consortium would constitute a premiere at the European and global level, which would support member states to select the most appropriate and efficient public response to various scenarios of human pandemic.


General objective
The present proposal`s main objective consists of utility analysis (cost-effectiveness) in terms of cost per Quality-Adjusted Life Year (QALY) saved in two fields: 1) Three population interventions (and their combinations) designed to prevent coronary artery disease incidence aimed at reducing smoking, dyslipidaemia, and hypertension population prevalence, and 2) optimal use of coronary angiography and percutaneous intervention procedures in the management of patients with acute coronary syndrome (ACS) with special emphasis on the elderly (>64 years) to minimize the inequalities in this patient subgroup that has higher mortality than patients <65 years.




Rare diseases (RD) have been identified as one of the paradigmatic fields in which actions conducted at the European level constitute the adequate response to their specific problems: poor recognition leading to diagnostic delay and inappropriate management including adapted social services, poor health outcomes, social burden, limited knowledge on natural history and pathophysiology leading to an insufficient development of new therapies. The low prevalence and the specificity of RD make that a global, multi-stakeholder approach, intended to gather specific expertise and to build shared strategies is necessary to address these issues.
The general objectives of RD-Action are to:
▪ Support the further development and sustainability of the Orphanet database, the biggest global repository of information on RD
▪ Contribute to solutions to ensure an appropriate codification of RD in health information systems
▪ Continue implementation of the priorities identified in Council Recommendation 2009/C151/02 and the Commission Communication (COM 2008 679) on RD, with a view to ensuring the sustainability of the recommended priority actions and to support the work of the Commission Expert Group on Rare Diseases (CEGRD).
This JA will expand and consolidate the achievements of the former JAs on RD supported by the European Commission: the Orphanet JA and the EUCERD JA. More precisely, this proposal has the ambition to help member states to implement the recommended measures adopted or to be adopted by the CEGRD and to produce the data necessary for countries to do so. Interactions between the production of data at the Orphanet database level and the implementation of policy priorities including codification will be strengthened during this JA.RD-Action large geographical coverage is key to success as it will promote the transfer of European recommendations into national policies and the collection of information and concerns from MS to the CEGRD, thus to the European Commission.



The PHIS project aims to increase the level of knowledge and exchange of information on pharmaceutical policies in the European Union. This will be achieved by surveying and monitoring pharmaceutical health system information in the inpatient and outpatient sector from a public health perspective, and by developing key pharmaceutical health indicators to be included in a European Health Information System.


The HoNCAB project is a timely initiative that strives to take advantage of the interval between the adoption of the Directive 2011/24/EU and its definitive application in the MSs. This is a delicate period in that many MSs may chose to apply either a more favourable approach or a more restrictive and budget conscious approach when transposing the Directive into National legislation. The chosen strategy hinges greatly on available information and this is where the HoNCAB project can fill the gap. Namely, by making available some preliminary but "real" data on the impact of patient mobility and by fine-tuning the methods of classification of the tariffs and the related techniques for comparison. Furthermore, the HoNCAB project aims to provide a framework for the launch of a pilot hospital network which will be quite extensive in its initial form and that will be designed to grow over time. Such a network will allow the participating hospitals to have a practical experience of the opportunities and critical issues of cross-border care and to share problems and solutions with other MS.
